Abstract
BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterismprinciple.Metabolites of 2, proposed from in vitrohumanmicrosome studies,were synthesized, leading to the identification of metabolite-derived analogue 10 with 40-350 pM potency against various cancer cell lines. Insights gained from the major inactive metabolite of 2 led to the development of 29, with better pharmacokinetics and improved potency in the tumor xenograft model than 2.
| Original language | English |
|---|---|
| Pages (from-to) | 4941-4945 |
| Number of pages | 5 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 52 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - Aug 13 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
Fingerprint
Dive into the research topics of 'Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS